Novartis AG (NVS) Analysts See $1.31 EPS as of July, 17

June 27, 2018 - By Ronnie Lemelle

Novartis AG (NYSE:NVS) Corporate Logo

Novartis AG (NYSE:NVS)’s earnings report is awaited on July, 17., as reported by RTT. Analysts have expectation on stock’s earnings per share of $1.31. That’s up 8.26 % from last year’s $1.21 earnings per share. If reported the P/E will be 14.01 with $3.37 billion profit. 2.34 % EPS growth is what Wall Street’s predicts after $1.28 reported EPS last quarter. NVS hit $73.43 during the last trading session after $0.21 change.Currently Novartis AG is downtrending after 6.45% change in last June 27, 2017. NVS has also 201,232 shares volume. The stock underperformed the S&P500 by 19.02%.

Novartis AG (NYSE:NVS) Ratings Coverage

In total 4 analysts cover Novartis (NYSE:NVS). “Buy” rating has 0, “Sell” are 0, while 4 are “Hold”. (NYSE:NVS) has 0 bullish analysts. 4 are the (NYSE:NVS)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Friday, February 2 the stock of Novartis AG (NYSE:NVS) earned “Hold” rating by Cowen & Co. On Tuesday, May 29 HSBC downgraded the shares of NVS in report to “Hold” rating. On Friday, May 25 the firm earned “Neutral” rating by Credit Suisse. In Thursday, January 25 report Leerink Swann maintained the stock with “Market Perform” rating.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.The company has $188.91 billion market cap. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.The P/E ratio is 21.53. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

For more Novartis AG (NYSE:NVS) news announced briefly go to: Fool.com, Seekingalpha.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” announced on June 24, 2018, “Novartis: Exit Sandoz US Now” on June 06, 2018, “Novartis (NVS) Granted FDA Approval for Inclusion of New Evidence that Cosentyx (secukinumab) Inhibits Progression …” with a publish date: June 19, 2018, “Here Are 43 Of 84 ‘Safer’ Healthcare High Yield Dividend Equities For June” and the last “Novartis’ Kymriah shows sustained benefit in DLBCL patients” with publication date: June 18, 2018.

Novartis AG (NYSE:NVS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.